Innate Pharma S.A. (IPHA) vs Invivyd (IVVD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Innate Pharma S.A. (IPHA) has outperformed Invivyd (IVVD) over the past year, losing 26.4% versus a loss of 57.3%. Over five years, IPHA leads with a -74.8% price change compared with -97.8% for IVVD. Invivyd is the larger company by market cap ($212.6 million vs $181.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPHA | IVVD |
|---|---|---|
| Share price | $1.62 | $0.7212 |
| Market cap | $180.95M | $212.58M |
| 1-day change | +9.46% | +2.97% |
| YTD return | -15.43% | -71.64% |
| 1-year return | -26.37% | -57.29% |
| 5-year return | -74.79% | -97.84% |
| EPS (TTM) | $-0.59 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.71 | $3.07 |
| 52-week low | $1.17 | $0.528 |
| Distance from 52-week high | -40.22% | -76.51% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +311.73% | +1286.58% |
| Average volume | 156.96K | 4.90M |
| Shares outstanding | 111.70M | 294.76M |
| Employees | 120 | 122 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPHA has outperformed IVVD by 30.9 percentage points over the past year.
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
IPHA vs IVVD FAQ
Which is bigger, Innate Pharma S.A. or Invivyd?
Invivyd (IVVD) is larger, with a market capitalization of $212.58M compared with $180.95M for Innate Pharma S.A. (IPHA).
Which stock has performed better over the past year, IPHA or IVVD?
IPHA returned -26.37% over the past 12 months, compared with -57.29% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Innate Pharma S.A. and Invivyd in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.